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Introduction:
Type I diabetes mellitus is an autoimmune disease characterized by the selective destruction of insulin-secreting β-cells found in pancreatic islets of Langerhans.
Although the initiation events leading to the development of disease are not wellcharacterized, inflammatory cytokines and the free radical, nitric oxide (NO), appear to play an important role. We and others have shown that treatment of isolated rat and human islets with cytokines such as interleukin-1 (IL-1), interferon-γ (IFN-γ) and TNF-α results in the inhibition of glucose-stimulated insulin secretion and islet degeneration.
The inhibitory and destructive effects of cytokines on β-cell function and islet viability are mediated, in part, through the expression of the inducible form of nitric oxide synthase (iNOS) and increased production of NO by β-cells (1-5). NO inhibits insulin secretion by targeting iron-sulfur containing enzymes such as aconitase and electrontransporting chain complexes I and II resulting in decreased oxidative phosphorylation and ATP production (6) (7) (8) (9) . Evidence in support of a role for nitric oxide in mediating cytokine-induced islet damage includes the protective actions of iNOS inhibitors aminoguanidine (AG) or N G -monomethyl L-arginine (L-NMMA) on cytokine-induced inhibition of on insulin secretion and islet degeneration ((1) (10) (11) (4)), and the lack of an inhibitory action of cytokines on glucose-stimulated insulin secretion in islets isolated from iNOS-deficient mice ( (12)). These results suggest that inflammatory cytokines mediate islet dysfunction and degeneration by inducing iNOS expression and NO formation by β-cells.
Three isoforms of cyclooxygenase (COX) have been characterized to date, two constitutive isoforms, COX-1 and COX-3, and an inducible isoform of the enzyme, COX-2 ( (13, 14) ). The product of the same COX-1 gene, COX-1 is expressed in most tissues whereas splice variant COX-3 appears to be localized primarily to neuronal tissue (13) . COX-2 is undetectable in most cells but may be induced in macrophages, fibroblasts, endothelial cells, monocytes and ovarian follicles in response to a number of stimuli including growth factors, bacterial endotoxins and cytokines (15) . Nitric oxide has been reported to activate COX-1 and COX-2 isoforms of the enzyme in macrophages, resulting in increased prostaglandin E 2 (PGE 2 ) formation ( (16)). In islets, cytokines have also been shown to induce the expression of the COX-2 resulting in increased production of PGE 2 ((17) (18) (19) (20) ). Similar to macrophages, nitric oxide stimulates COX-1 and COX-2 enzymatic activities in rat and human islets ((18,19) ). These results suggest that cytokines stimulate both iNOS and COX-2 expression in islets and that NO contributes to the accumulation of proinflammatory prostaglandins by stimulating the enzymatic activity of COX-1 and COX-2.
Numerous investigators have studied the effects of nonsteroidal, antiinflammatory drugs (NSAIDs), which inhibit both COX-1 and COX-2 activities, on insulin secretion both in vivo and ex vivo in isolated islet preparations. Increases in basal insulin, first-phase insulin response, 2 nd phase or total insulin and improved glucose tolerance have been observed in normal and diabetic patients following treatment with sodium salicylate, acetosalicylic acid, and ibuprofen ( (21)). In addition, PGE 2 has been shown to decrease insulin secretion and glucose tolerance in normal human subjects.
Together, these data suggest that COX activity or COX-derived PGE 2 modulates insulin secretion and glucose tolerance in normal and diabetic patients. In vitro, sodium salicylate, acetosalicylic acid, and ibuprofen appear to augment glucose-stimulated insulin secretion by isolated rat islets ((21)). Salicylates have also been shown to attenuate cytokine-mediated inhibition of insulin secretion by rat islets ( (22)). Recent reports suggest that selective inhibition of COX-2 attenuates diabetes development in the low-dose streptozotocin (STZ) mouse model and protects rat islets from cytokine-induced inhibition of glucose-stimulated insulin secretion ((23) (24)) implicating COX-2 and COX-2-derived PGE 2 in cytokine-mediated β-cell dysfunction and diabetes development.
In contrast, indomethacin, a more potent COX inhibitor than the salicylates, decreases first-phase insulin secretion and glucose tolerance in normal human subjects ( (21) Hepes, 115 mM NaCl, 24 mM NaHCO 3 , 5 mM KCl, 1 mM MgCl 2 , 2.5 mM CaCl 2 , and 0.1% BSA, pH 7.4) containing 3 mM D-glucose and insulin secretion was performed in the presence of either 3 mM or 20 mM D-glucose as described ( (4)). Medium insulin content was determined by radioimmunoassay ( (27)).
Islet viability: Islets (25/500 µl of complete CMRL-1066) were cultured for 96 h in 24-well microtiter plates with the indicated concentrations of cytokines, PGE 2 +/-SC-58236
or Celebrex. Islet degeneration was determined in a blinded fashion by phase-contrast microscopic analysis. Islet degeneration is characterized by the loss of islet integrity as assessed by disintegration and partial dispersion of islets as described previously ((28) (11)).
Western blot analysis:
Rat or human islets (120/400 µl of complete CMRL-1066), cultured for the indicated times with cytokines, PGE 2 , SC-58236 or Celebrex, +/-AG or NMMA, were isolated, lysed, and protein separated by SDS-gel electrophoresis as described ( (4)). Detection of rat iNOS (1:5000 dilution), rat COX-2 (1:100 dilution), human iNOS (1:500 dilution), human COX-2 (1:1000 dilution), human COX-1 (1:1000 dilution) were by ECL according to manufacturer's specifications (Amersham, Arlington
Heights, IL).
Nitrite and Prostaglandin E 2 Determination: Nitrite production was determined by mixing 50 µl of culture medium with 50 µl of Griess reagent ( (29)). The absorbance at 540 nm was measured and nitrite concentrations were calculated from a sodium nitrite standard curve. Prostaglandin E 2 production was determined by using a monoclonal Prostaglandin E 2 EIA kit (Cayman Chemical, Ann Arbor, MI) according to the manufacturer specifications.
Statistical Analyses: Statistical comparisons were made between groups using a oneway analysis of variance. Significant differences between treatment groups compared with untreated controls (p< 0.05) were evaluated using a Least Significant Differences posthoc analysis.
Results:

Time-dependent effects of IL-1β on COX-2 expression and PGE 2 formation by rat islets.
Previous studies have shown that IL-1β induces the time-dependent production of nitric oxide and PGE 2 by rat islets that is maximal following 48 h incubation ( (19) and Fig 1a) .
To characterize the time-dependent expression of COX-2, rat islets were incubated for 0-48 h with 1 unit/ml IL-1β followed by Western blot analysis of COX-2 protein expression by isolated rat islets.
Effects of COX-2 inhibition on IL-1β -induced NO and PGE 2 formation by rat islets.
To examine the effects of selective COX-2 inhibition on islet PGE 2 accumulation and NO formation, rat islets were incubated for 40 h with 1 unit/ml IL-1β in the presence or absence of 25 ng/ml SC-58236 (30) . As shown in Figure 2 , IL-1β induces a ~7-fold increase in both PGE 2 and nitrite production following a 40 h incubation. The COX-2-selective inhibitor SC-58236 (25 ng/ml) prevents IL-1β-induced PGE 2 formation ( Figure   2a ) without affecting IL-1β-induced nitrite production by rat islets (Figure 2b ).
Consistent with previous studies, the iNOS-selective inhibitor, AG, prevents IL-1β-induced nitrite production ( Figure 2b ) and significantly attenuates IL-1β-induced PGE 2 formation by rat islets ( (18) (8) (5) and Figure 3 ). Recent data has implicated COX-2-derived PGE 2 production as a mediator of IL-1-induced inhibition of insulin secretion by rat islets ( (23)). To determine whether inhibition of COX-2 activity and PGE 2 formation protects islets from the inhibitory and destructive effects of IL-1β on glucose-stimulated insulin secretion and islet viability, islets were incubated with 1 unit/ml IL-1β in the presence or absence of SC-58236 (25 ng/ml) and exogenous PGE 2 (1 µM). Treatment of rat islets with IL-1β results in a ~68% inhibition of glucose-stimulated insulin secretion following 40 h incubation ( Fig. 3a) and ~98% islet morphological degeneration following 96 h incubation (Fig. 3b) . SC-58236, which prevents IL-1β-induced PGE 2 formation (Fig. 2a) does not prevent the inhibitory actions of IL-1β on insulin secretion, nor does it prevent islet degeneration. Addition of exogenous PGE 2 (1 µM) does not impair glucosestimulated insulin secretion nor does it stimulate islet degeneration. Preincubation of islets with the selective iNOS inhibitor, AG, prevents both the inhibitory actions of IL-1β on insulin secretion and the destructive effects of IL-1β on islet viability. These results indicate that selective inhibition of COX-2 does not prevent IL-1β -induced β-cell dysfunction and damage. These findings also support a primary role for nitric oxide as the mediator of cytokine-induced inhibition of insulin secretion and islet morphological degeneration.
Effects of IL-1β+IFN-γ on COX-2 expression and PGE 2 formation by human islets.
While IL-1β alone is sufficient to induce iNOS and COX-2 expression and NO and PGE (Fig 4b) . Consistent with COX-2 expression, PGE 2 accumulation is first apparent following 12 h incubation and the levels continue to increase to maximal (~11-fold) levels following 40-48h incubation. Similar to COX-2 expression, this combination of cytokines stimulates the time-dependent expression of iNOS that is first apparent following a 6 h incubation and maximal following a 40-48 h incubation (Fig 4b) . Cytokine-induced NO formation by human islets is also time- 
Effects of Celebrex on cytokine-induced islet degeneration and inhibition of glucosestimulated insulin secretion.
To determine whether PGE 2 formation mediates cytokineinduced inhibition of glucose-stimulated insulin secretion and islet degeneration, human islets were incubated with a mixture of cytokines in the presence and absence of Celebrex. As shown in Figure 6 , incubation of human islets with IL-1β + IFN-γ + TNFα, results in a ~79% inhibition of glucose-stimulated insulin secretion following a 48 h incubation and ~96% islet morphological degeneration following 96 h incubation. Coincubation of islets with 10 uM Celebrex, which prevents cytokine-stimulated PGE 2 formation, fails to prevent the inhibitory and destructive effects of cytokines on glucosestimulated insulin secretion and islet viability. Alone, neither exogenous PGE 2 nor
Celebrex inhibit basal or glucose-stimulated insulin secretion, or induce human islet degeneration ( Figure 6 and data not shown). These results indicate that selective inhibition of COX-2 fails to protect islets from the inhibitory and destructive effects of cytokines on glucose-induced insulin secretion and islet viability. These data suggest that cytokine-induced PGE 2 formation does not mediate the inhibitory and destructive effects of cytokines on β-cell function and islet viability by human islets.
Discussion:
Insulin 1) (5)) and the lack of an inhibitory action of cytokines on glucosestimulated insulin secretion in islets isolated from iNOS-deficient mice ( (12)).
In addition to iNOS expression, cytokines have been shown to induce COX-2 expression and PGE 2 production both in isolated rat and human islets; however, the role of COX-2-derived PGE 2 on β-cell function and viability has not been fully characterized.
In this study, we have characterized the temporal expression of COX-2 and production of PGE 2 by rat and human islets and determined whether selective COX-2 inhibition prevents cytokine-mediated islet dysfunction and damage. Treatment of rat and human islets with IL-1β and IL-1β + IFN-γ (+/-TNF-α), respectively, results in the time-dependent production of PGE 2 that is maximal following 24-48 h incubation. Cytokineinduced PGE 2 formation by rat and human islets correlates with cytokine-induced COX-2 expression that is first observed following 3 h incubation and remains at detectable levels of expression following 40-48 h incubation. Selective inhibition of COX-2 in rat and human islets by SC-58236 or Celebrex, respectively, at concentrations that completely inhibit cytokine-induced PGE 2 formation, does not protect islets from cytokine-induced inhibition of glucose-stimulated insulin secretion or islet morphological degeneration.
These results suggest that although cytokine-induced PGE 2 production and COX-2 expression correlate with cytokine-induced inhibition of glucose-stimulated insulin secretion, islet production of PGE 2 does not mediate these inhibitory and destructive effects.
With the exception of indomethacin, NSAIDs as a class have been shown to increase glucose-stimulated insulin secretion by isolated rat islets in vitro, and to improve glucose tolerance in diabetic and normal human subjects ( (21)); however, the mechanism by which NSAIDs mediate these beneficial effects is unclear. Previous reports support the hypothesis that NSAIDs exert their beneficial effects via inhibition of COX-2 activity and COX-2-derived PGE 2 production. The selective COX-2 inhibitor, NS-398, has been shown to attenuate diabetes development in the low-dose STZ mouse model and selective COX-2 inhibition by SC-58236 has been shown to attenuate IL-1-induced inhibition of glucose-stimulated insulin secretion by Wistar rat islets ( (23) (24)). However, data obtained in the current study indicate that selective COX-2 inhibition by SC-58236 fails to prevent the inhibitory effects of IL-1β on glucose-stimulated insulin secretion by isolated Sprague-Dawley rat islets. The addition of supraphysiological concentrations of PGE 2 , either alone or in combination with cytokine(s) and COX-2 inhibitor(s), also does not inhibit glucose-stimulated insulin secretion or induce islet damage by rat and human islets. These data are consistent with previous reports in which exogenous PGE 2 failed to mimic the inhibitory actions of IL-1 on glucose-stimulated insulin secretion by isolated rat islets ( (17)) and in which indomethacin, at concentrations that completely inhibit islet PGE 2 production, did not attenuate the inhibitory effects of IL-1 on β-cell function ( (11, 17) ).
To determine whether the strain of rat utilized for these studies could explain these discordant results, we examined whether SC-58236 prevents the inhibitory actions of IL-1 on glucose-stimulated insulin secretion by isolated Wistar rat islets. Similar to islets isolated from Sprague-Dawley rats, SC-58236 fails to prevent the inhibitory actions of IL-1β on glucose-stimulated insulin secretion by Wistar rat islets (data not shown).
These data suggest that the discordant results are not due to differences in the strain of rat utilized for experimentation. The studies are otherwise very similar in execution with the exception of the conditions used to culture the islets. Following isolation, rat (SpragueDawley and Wistar) and human islets used in the current study were cultured in CMRL-1066 medium containing 5 mM glucose. In contrast, Wistar rat islets were cultured in RPMI-1640 medium containing 11 mM glucose in the study by Tran et al ( (23)).
Previous reports indicate that COX-2 expression is increased in vascular smooth muscle and endothelial cells when cultured in high glucose ((34,35) ), and in monocytes isolated from Type I and Type II diabetic individuals ( (36)). In addition, Persaud et al. recently
reported that, whereas freshly isolated mouse islets express primarily COX-1, COX-2 expression is induced and becomes the primary isoform of COX expressed in islets that are cultured in high glucose ( (37)). In a concentration-dependent manner, glucose also induces COX-2 expression in human islets ( (37)). Consistent with these data, in a separate report published by the same laboratory as the Tran et al. study, human islets cultured in RPMI-1640 medium containing 11 mM glucose were shown to constitutively express COX-2 as the dominant COX isoform ( (20)). Although islets cultured in high glucose constitutively express COX-2, they appear to function normally, secreting insulin in response to a high glucose challenge (23) . The addition of exogenous PGE 2 also does not modulate glucose-stimulated insulin secretion ( (17), current study) suggesting that increased COX-2 expression and PGE 2 formation do not adversely affect β-cell function.
Taken together, these data indicate that islets do not constitutively express COX-2 as the predominant isoform of COX under basal glucose culture conditions, and that increased COX-2 expression and PGE 2 formation do not modulate β-cell function or mediate the inhibitory and destructive effects of cytokines on glucose-stimulated insulin secretion and islet viability.
One mechanism by which salicylates (sodium salicylate, acetosalicylic acid) appear to exert their beneficial effects on insulin secretion and glucose tolerance is via inhibition of IκB kinase (IKKβ; (38) ). IKKα and IKKβ phosphorylate the IκB proteins, which sequester the transcription factor, NF-κB in quiescent cells. Once phosphorylated by IKK, IκB dissociates from the NF-κB:IκB complex allowing NF-κB to translocate to the nucleus and induce gene transcription ( (39)). IL-1-induced iNOS and COX-2 expression in islets requires the activation of NF-κB ( (40)). Recent data suggests the mechanism by which salicylates attenuate cytokine-induced inhibition of insulin secretion is via inhibition of NF-κB activation and subsequent inhibition of COX-2 expression ( (22)). However, since salicylates also inhibit iNOS expression and NO formation by rat islets ( (41)), and inhibitors of iNOS activity prevent the damaging actions of cytokines on the function and viability of rat and human islets, it would be reasonable to conclude that salicylates attenuate cytokine-mediated damage by preventing IKK-mediated NF-κB activation and subsequent expression of iNOS by islets.
In support of this hypothesis, we have shown that selective inhibition of COX-2 fails to prevent cytokine-induced inhibition of glucose-stimulated insulin secretion and islet degeneration in rat and human islets. However, selective inhibition of iNOS by AG or NMMA, prevents the inhibitory and destructive effect of cytokines on β-cell function and viability in accordance with previous reports ((5)). Taken together, these data provide support for the hypothesis that the mechanism by which salicylates attenuate cytokinemediated inhibitory and destructive effects on β-cell function and islet viability may be via inhibition of IKKβ activity and subsequent prevention of cytokine-induced NF-κB-mediated expression of iNOS by β-cells.
In conclusion, the results of the current study indicate that selective inhibition of COX-2 activity by SC-58236 or Celebrex fails to protect rat and human islets, respectively, from cytokine-induced inhibition of glucose-stimulated insulin secretion and islet degeneration. These results suggest that the inhibitory and destructive effects of cytokines on islet function and viability are not mediated by cytokine-induced production of PGE 2 by islets and provide further support for cytokine-induced iNOS expression and NO formation as mediators of these inhibitory and destructive effects. by guest on August 17, 2017 
